About: http://data.cimple.eu/news-article/d8ff0c250a9f62a6793c04fa3166416641667c16b0f535334fd6185b

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/d8ff0c250a9f62a6793c04fa3166416641667c16b0f535334fd6185b Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	French pharmaceuticals giant Sanofi and Britain's GSK reported on Monday "strong immune responses" in early tests of their Covid-19 vaccine, raising hopes it could join the fight against the pandemic. The companies said the results of the Phase 2 study will enable them to move to a late-stage trial in the coming weeks -- a reversal of fortune after their research was dealt a setback late last year. The experimental vaccine "achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers," it said in a statement. "A global pivotal Phase 3 study is expected to start in the coming weeks." An earlier study in late 2020 showed the vaccine provided a low immune response in older adults. The companies said the vaccine would not be ready until the end of 2021. The initial failure was a setback that dented French pride as France is the only permanent member of the UN Security Council not to have its own vaccine after successes for Britain, China, Russia and the United States. "Our Phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis," said Thomas Triomphe, executive vice president and global head of Sanofi Pasteur. "As we know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines, which can be stored at normal temperatures, increases," he said. The firms are combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK's adjuvant technology, a substance that bolsters the immune response triggered by a vaccine. lem/ak/wdb/lth
schema:headline	Sanofi, GSK say Covid vaccine shows positive result
schema:mentions	Dented Records Antigen Influenza pandemic USA Gymnastics United Nations Security Council AK-47 Clarence Thomas French language Public health Antibody Russian Empire France Coronavirus disease Vaccine United States China Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Sanofi Pasteur Adjuvant Immunogenicity Sanofi
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-05-17 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	90 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software